-
公开(公告)号：US20230235217A1
公开(公告)日：2023-07-27
申请号：US17919015
申请日：2021-03-29
申请人： KONICA MINOLTA, INC.
发明人： Shumpei Hitosugi
IPC分类号： C09K11/06 , C07D471/06 , C07D491/16 , C07D495/06 , C09B57/00 , C07F5/02
CPC分类号： C09K11/06 , C07D471/06 , C07D491/16 , C07D495/06 , C09B57/00 , C07F5/02
摘要： A luminescent compound has a structure represented by a general formula (1),
wherein R represents a luminescent dye skeleton, X represents an ionic substituent, and L represents a single bond, an oxygen atom, a sulfur atom, a selenium atom, or an NH group.-
2.发明授权公开(公告)号：US11335862B2
公开(公告)日：2022-05-17
申请号：US16575109
申请日：2019-09-18
发明人： Jungsub Lee , Hyein Jeong , Hye Jeong Park
IPC分类号： H01L51/00 , C07F5/02 , C09K11/06 , C07D495/06 , H01L51/50
摘要： An organic electroluminescence device according to an embodiment of the present disclosure includes a first electrode, a hole transport region, an emission layer, an electron transport region, and a second electrode, in which the emission layer includes a polycyclic compound represented by Formula 1, thereby achieving improved emission efficiency:
-
公开(公告)号：US10246458B2
公开(公告)日：2019-04-02
申请号：US15943714
申请日：2018-04-03
发明人： Thomas Armer , Geoff McKinley , Scott Borland , Miguel Guzman , Ármin Szabolcs , János Gerencser
IPC分类号： C07D457/06 , A61K31/48 , C07D471/06 , C07D495/06
摘要： Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.
-
公开(公告)号：US20190036059A1
公开(公告)日：2019-01-31
申请号：US16014245
申请日：2018-06-21
发明人： Zhiqiang Ji , Bin Ma
IPC分类号： H01L51/50 , H01L51/52 , H01L51/00 , C07D495/16 , C07D495/06 , C07D495/22 , C07D487/16 , C07D487/06 , C07D487/22 , C07D519/00 , C07C13/62
摘要： Circulene compounds of Formula I or Formula II, and organic light emitting devices (OLED) that include an organic layer disposed between an anode and a cathode, wherein the organic layer includes a compound of Formula I or Formula II. In addition, the OLED can be incorporated into one or more of a consumer product, for example, an electronic component module, and/or a lighting panel.
-
公开(公告)号：US10193070B2
公开(公告)日：2019-01-29
申请号：US15518854
申请日：2015-10-20
IPC分类号： C07D487/06 , C07D493/06 , C07D495/06 , H01L51/00 , C09K11/02 , H01L51/50 , H01L51/52 , C08G73/02 , C07D517/06
摘要： There is disclosed a compound having Formula I, Formula II, Formula III, Formula VIII, Formula IX, or Formula X The variables are described in detail in the application.
-
公开(公告)号：US20180327404A1
公开(公告)日：2018-11-15
申请号：US15943714
申请日：2018-04-03
发明人： Thomas Armer , Geoff McKinley , Scott Borland , Miguel Guzman , Ármin Szabolcs , János Gerencser
IPC分类号： C07D471/06 , C07D495/06
CPC分类号： C07D471/06 , C07D495/06
摘要： Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.
-
公开(公告)号：US20180033974A1
公开(公告)日：2018-02-01
申请号：US15437504
申请日：2017-02-21
发明人： Jungsub LEE
IPC分类号： H01L51/00 , C07D495/06 , C07D401/10 , C07D491/06 , C09K11/06 , C09K11/02
CPC分类号： H01L51/0067 , C07D401/10 , C07D491/06 , C07D495/06 , C09K11/025 , C09K11/06 , C09K2211/1007 , C09K2211/1029 , C09K2211/185 , H01L51/0052 , H01L51/0071 , H01L51/0072 , H01L51/0085 , H01L51/5012 , H01L51/5016 , H01L51/5072 , H01L51/5092
摘要： A polycyclic compound and an organic light-emitting device, the compound being represented by Formula 1:
-
公开(公告)号：US09790236B2
公开(公告)日：2017-10-17
申请号：US13349141
申请日：2012-01-12
申请人： Jeong-il Park , Bang Lin Lee , Jong Won Chung
发明人： Jeong-il Park , Bang Lin Lee , Jong Won Chung
IPC分类号： C07D513/06 , C07D495/06 , H01L51/00 , H01L51/05
CPC分类号： C07D513/06 , C07D495/06 , H01L51/0036 , H01L51/0043 , H01L51/0068 , H01L51/0071 , H01L51/0558
摘要： An example embodiment relates to an organic semiconductor compound, represented by Chemical Formula 1 herein, which may be polymerized and used in transistors and electronic devices. The organic semiconductor compound includes a base structure of four fused benzene rings with functional groups R1 to R3 connected to a first benzene ring and with functional groups R4 to R6 connected to a second benzene ring. The base structure's third and fourth benzene rings are connected to X1, X2 and X3, X4 respectfully. At least one of X1 and X2 is a sulfur atom. At least one of X3 and X4 is a sulfur atom. The base structure further includes functional groups R7 and R8.
-
公开(公告)号：US20170271596A1
公开(公告)日：2017-09-21
申请号：US15296852
申请日：2016-10-18
发明人： Jungsub Lee
IPC分类号： H01L51/00 , C07D471/06 , C07D401/10 , C07D491/06 , C07D495/06 , C07D401/04 , H01L51/50 , C07D519/00
CPC分类号： H01L51/0072 , C07D401/04 , C07D401/10 , C07D401/14 , C07D471/06 , C07D491/06 , C07D495/06 , C07D519/00 , C09K11/06 , H01L51/005 , H01L51/0067 , H01L51/0071 , H01L51/0077 , H01L51/0081 , H01L51/0085 , H01L51/5016 , H01L51/5056 , H01L51/506 , H01L51/5072 , H01L51/5088 , H01L51/5092 , H01L51/5096
摘要： A compound is represented by one selected from Formulae 1 and 2: Wherein the components of Formulae 1 and 2 are each independently defined as set forth in the present disclosure. An organic light-emitting device includes at least one of the compound represented by one selected from Formulae 1 and 2.
-
公开(公告)号：US09657020B2
公开(公告)日：2017-05-23
申请号：US15001252
申请日：2016-01-20
发明人： Thomas Armer , Geoff McKinley , Scott Borland , Miguel Guzman , Ármin Szabolcs , János Gerencser
IPC分类号： C07D457/06 , C07D457/02 , C07D471/06 , C07D495/06
CPC分类号： C07D471/06 , C07D495/06
摘要： Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.
-
-
-
-
-
-
-
-
-
搜索结果
195 条记录 (耗时 0.034 秒)
